Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 944.92 Million CNY | -22.88% |
| 2022 | 2.33 Billion CNY | 14.82% |
| 2021 | 2.03 Billion CNY | -2.62% |
| 2020 | 2.08 Billion CNY | 21.0% |
| 2019 | 1.72 Billion CNY | -10.61% |
| 2018 | 1.93 Billion CNY | 201.6% |
| 2017 | 640 Million CNY | -11.52% |
| 2016 | 723.33 Million CNY | -14.77% |
| 2015 | 848.72 Million CNY | 50.12% |
| 2014 | 565.37 Million CNY | 50.28% |
| 2013 | 376.2 Million CNY | -43.63% |
| 2012 | 667.37 Million CNY | -7.31% |
| 2011 | 720.04 Million CNY | -55.6% |
| 2010 | 1.62 Billion CNY | 51.05% |
| 2009 | 1.07 Billion CNY | 339.3% |
| 2008 | 244.39 Million CNY | 134.72% |
| 2007 | 104.12 Million CNY | 21.43% |
| 2006 | 85.74 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 473.7 Million CNY | 3.49% |
| 2024 Q2 | 514.55 Million CNY | 8.62% |
| 2023 Q3 | 386.54 Million CNY | -23.0% |
| 2023 Q2 | 501.98 Million CNY | 10.56% |
| 2023 Q4 | 457.74 Million CNY | 18.42% |
| 2023 Q1 | 454.02 Million CNY | -23.53% |
| 2023 FY | 1.8 Billion CNY | -22.88% |
| 2022 Q2 | 645.25 Million CNY | 11.41% |
| 2022 Q4 | 593.76 Million CNY | 15.02% |
| 2022 FY | 2.33 Billion CNY | 14.82% |
| 2022 Q1 | 579.16 Million CNY | 0.47% |
| 2022 Q3 | 516.21 Million CNY | -20.0% |
| 2021 FY | 2.03 Billion CNY | -2.62% |
| 2021 Q1 | 417.97 Million CNY | -39.95% |
| 2021 Q2 | 564.11 Million CNY | 34.96% |
| 2021 Q3 | 474.49 Million CNY | -15.89% |
| 2021 Q4 | 576.44 Million CNY | 21.49% |
| 2020 Q3 | 271.73 Million CNY | -46.17% |
| 2020 Q2 | 504.84 Million CNY | -17.93% |
| 2020 Q1 | 615.16 Million CNY | 0.17% |
| 2020 FY | 2.08 Billion CNY | 21.0% |
| 2020 Q4 | 696.05 Million CNY | 156.15% |
| 2019 Q1 | 366.87 Million CNY | -40.63% |
| 2019 Q2 | 374.06 Million CNY | 1.96% |
| 2019 Q3 | 370.4 Million CNY | -0.98% |
| 2019 Q4 | 614.13 Million CNY | 65.8% |
| 2019 FY | 1.72 Billion CNY | -10.61% |
| 2018 Q1 | 251.81 Million CNY | 10.68% |
| 2018 FY | 1.93 Billion CNY | 201.6% |
| 2018 Q2 | 407.95 Million CNY | 62.01% |
| 2018 Q3 | 446.15 Million CNY | 9.36% |
| 2018 Q4 | 617.94 Million CNY | 38.5% |
| 2017 Q4 | 227.5 Million CNY | 54.73% |
| 2017 Q1 | 111.11 Million CNY | -45.47% |
| 2017 FY | 640 Million CNY | -11.52% |
| 2017 Q2 | 154.36 Million CNY | 38.93% |
| 2017 Q3 | 147.03 Million CNY | -4.75% |
| 2016 Q4 | 203.75 Million CNY | 77.04% |
| 2016 Q2 | 156.98 Million CNY | -36.58% |
| 2016 Q1 | 247.51 Million CNY | -8.73% |
| 2016 FY | 723.33 Million CNY | -14.77% |
| 2016 Q3 | 115.08 Million CNY | -26.69% |
| 2015 Q4 | 271.18 Million CNY | 82.82% |
| 2015 FY | 848.72 Million CNY | 50.12% |
| 2015 Q3 | 148.33 Million CNY | -7.9% |
| 2015 Q2 | 161.06 Million CNY | -39.93% |
| 2015 Q1 | 268.13 Million CNY | 77.52% |
| 2014 Q3 | 196.23 Million CNY | 23.74% |
| 2014 Q1 | 59.5 Million CNY | 66.48% |
| 2014 Q4 | 151.04 Million CNY | -23.03% |
| 2014 FY | 565.37 Million CNY | 50.28% |
| 2014 Q2 | 158.58 Million CNY | 166.51% |
| 2013 Q4 | 35.74 Million CNY | -42.14% |
| 2013 FY | 376.2 Million CNY | -43.63% |
| 2013 Q1 | 151.77 Million CNY | -3.43% |
| 2013 Q2 | 126.91 Million CNY | -16.38% |
| 2013 Q3 | 61.77 Million CNY | -51.33% |
| 2012 Q3 | 151.05 Million CNY | -9.11% |
| 2012 Q2 | 166.2 Million CNY | -13.86% |
| 2012 FY | 667.37 Million CNY | -7.31% |
| 2012 Q1 | 192.94 Million CNY | 49.39% |
| 2012 Q4 | 157.17 Million CNY | 4.05% |
| 2011 Q3 | 153.29 Million CNY | -36.46% |
| 2011 Q1 | 196.35 Million CNY | -44.73% |
| 2011 FY | 720.04 Million CNY | -55.6% |
| 2011 Q4 | 129.15 Million CNY | -15.74% |
| 2011 Q2 | 241.23 Million CNY | 22.86% |
| 2010 Q1 | 353.3 Million CNY | -24.27% |
| 2010 FY | 1.62 Billion CNY | 51.05% |
| 2010 Q4 | 355.28 Million CNY | -23.28% |
| 2010 Q3 | 463.12 Million CNY | 2.9% |
| 2010 Q2 | 450.07 Million CNY | 27.39% |
| 2009 FY | 1.07 Billion CNY | 339.3% |
| 2009 Q1 | 173.09 Million CNY | 0.0% |
| 2009 Q3 | 242.02 Million CNY | 26.06% |
| 2009 Q4 | 466.53 Million CNY | 92.76% |
| 2009 Q2 | 191.99 Million CNY | 10.92% |
| 2008 FY | 244.39 Million CNY | 134.72% |
| 2007 FY | 104.12 Million CNY | 21.43% |
| 2006 FY | 85.74 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | -464.349% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 85.516% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -3183.378% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | -139.334% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 2754.056% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | -71.396% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 38.613% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | -100.496% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -336.194% |
| SSY Group Limited | 3.48 Billion HKD | 72.918% |
| JBM (Healthcare) Limited | 319.41 Million HKD | -195.828% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | -52.29% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 97.821% |